British Lifesciences, a pioneering force in the pediatric and gynaecological nutrition sectors, has achieved a remarkable milestone. This Bangalore-based company has surpassed 100 crores in sales within just seven years of operation. This exceptional accomplishment underscores the company’s dedication to providing high-quality, science-backed nutritional solutions for infants, children, and mothers.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Founded in 2013 as a division of British Biologicals, British Lifesciences has rapidly established itself as a trusted name in the industry. Under the visionary leadership of VS Reddy, a renowned expert in nutrition and healthcare, the company has focused on developing specialised products that address the unique nutritional needs of infants and children.

“Crossing the 100 crore mark in just seven years is a reflection of our team's hard work and dedication to improving the health and well-being of children and mothers across the country,” said VS Reddy, Managing Director of British Lifesciences.

Known as Protein People, the dedicated team of medical professionals, dietitians, and nutrition experts at British Lifesciences is committed to developing high-quality nutritional supplements. Since its inception in 1992, British Biologicals has expanded its reach to over 30 countries worldwide, and British Lifesciences aspires to become a global leader in nutrition care.

British Lifesciences offers a comprehensive range of products, including specialised infant formulas, baby cereals, maternal nutrition supplements, and nutritional solutions for children. The company’s commitment to research and development has led to the creation of innovative products like LF 100, AARIN (Gync), ARKA-D (Gummies), and MMS Casein.

As British Lifesciences continues to grow and expand its reach, the company remains committed to its mission of providing affordable and accessible nutrition for all. 

 

 

(This article is part of IndiaDotCom Pvt Lt’s sponsored feature, a paid publication programme. IDPL claims no editorial involvement and assumes no responsibility or liability for any errors or omissions in the content of the article.)